NTRK2(TRKB)
Sign in to save this workspaceUniProt Q16620 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: Cytoplasmic (455-end)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Cabozantinib | 100.0% | 0.0% | 92.73 | 0.751 |
| 2 | Repotrectinib | 99.8% | 0.2% | 84.21 | 0.608 |
| 3 | Entrectinib | 99.8% | 0.2% | 93.69 | 0.671 |
| 4 | Pralsetinib | 99.4% | 0.6% | 93.43 | 0.643 |
| 5 | Alpelisib | 99.3% | 0.7% | 97.22 | 0.720 |
| 6 | Crizotinib | 98.5% | 1.5% | 91.39 | 0.581 |
| 7 | Ponatinib | 98.4% | 1.6% | 78.23 | 0.534 |
| 8 | Larotrectinib | 97.9% | 2.1% | 99.25 | 0.710 |
| 9 | Tenalisib | 95.3% | 4.7% | 97.98 | 0.702 |
| 10 | Gilteritinib | 94.2% | 5.8% | 88.97 | 0.506 |
| 11 | Defactinib | 91.3% | 8.7% | 92.68 | 0.450 |
| 12 | Pacritinib | 91.2% | 8.8% | 88.64 | 0.452 |
| 13 | Lorlatinib | 90.5% | 9.5% | 97.24 | 0.694 |
| 14 | Darovasertib | 88.9% | 11.1% | 96.99 | 0.719 |
| 15 | Bosutinib | 85.6% | 14.4% | 87.22 | 0.555 |
| 16 | Tivozanib | 84.5% | 15.5% | 92.42 | 0.673 |
| 17 | Sunitinib | 79.0% | 21.0% | 91.73 | 0.524 |
| 18 | Midostaurin | 76.2% | 23.8% | 78.64 | 0.500 |
| 19 | Ripretinib | 68.9% | 31.1% | 92.95 | 0.674 |
| 20 | Futibatinib | 65.5% | 34.5% | 98.48 | 0.718 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.46
- Epithelial log2(TPM+1): 0.47
- Fold change: -0.01
- Status: No significant change
Selectivity landscape vs inhibition on NTRK2
Each point is one of the 92 approved drugs; color = inhibition % on NTRK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…